AstraZeneca shares the latest overall survival (OS) data for IMFINZI® in combination with IMJUDO®
AstraZeneca recently shared the latest overall survival (OS) data for IMFINZI® (durvalumab) in combination with IMJUDO®(tremelimumab-actl) for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).1,2 Primary AnalysisThe primary analysis demonstrated statistically significant improvement in the primary endpoint of OS vs sorafenib in the first-line (1L) treatment of uHCC1,2: *The HR is based on the stratified Cox proportional hazards […]